A
ArmaGen Technologies
ArmaGen | Revolutionary Therapies for Severe Neurological Diseases | ArmaGen
About ArmaGen Technologies
ArmaGen is a biopharmaceutical company focused on developing innovative therapies for severe neurological diseases. The company specializes in engineering biopharmaceuticals that can cross the blood-brain barrier, a critical challenge in treating brain disorders. ArmaGen's core technology involves the use of fusion proteins, which combine therapeutic agents with antibodies that facilitate transport across the blood-brain barrier. This approach aims to deliver effective treatments directly to the brain, addressing conditions that are otherwise difficult to treat.
Read full description
ArmaGen primarily serves patients suffering from rare and severe neurological conditions, including lysosomal storage diseases and other genetic disorders. The company operates in the biopharmaceutical market, targeting a niche segment with high unmet medical needs. ArmaGen's business model involves the research, development, and commercialization of its proprietary therapies. Revenue is generated through partnerships, licensing agreements, and eventual product sales once therapies receive regulatory approval.
The company's innovative approach has shown promising results in preclinical and early clinical studies, demonstrating the potential to significantly improve patient outcomes. ArmaGen continues to advance its pipeline of therapeutic candidates, leveraging its expertise in blood-brain barrier transport technology to address a range of neurological diseases.
At a glance
- Status
- Acquired
- Founded
- 2001
- Headquarters
- Calabasas, United States
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 45.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Oncology, Neurology, Disease, Biotech and Pharma, Hard Tech, medical testing, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Mar 2020 | $0 | — | JCR Pharmaceuticals | ↗ |
| EARLY VCEquity / VC | Feb 2018 | $10M | $40M | Undisclosed | — |
Growth signals
Latest recorded traffic for ArmaGen Technologies is 210 monthly website visits, down 58.8% over the last three months. ArmaGen Technologies's team grew 16.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Boehringer Ingelheim Venture Fund
Takeda Ventures
Mitsui Global Investment
Shire
Other known investors3 additional known investors
JCR Pharmaceuticals
Small Business Innovation Research
Takeda
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ArmaGen Technologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ArmaGen Technologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.